Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats
Molecular Metabolism · 2027-01 · 115 · 102464
DOI: 10.1016/j.molmet.2026.102464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Metabolism, 2027-01. Verfasst von Lisbeth M Petersen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Novo Nordisk A/S, Måløv and Søborg, Denmark. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
PURPOSE: CagriSema (CS), combining the amylin receptor agonist cagrilintide with the glucagon-like peptide 1 receptor agonist semaglutide, is being developed for obesity and type 2 diabetes. We quantified CS effects on energy balance during initial treatment, weight maintenance, and after discontinuation. METHODS: Male diet-induced obese rats underwent indirect calorimetry during 6 weeks of treatment and for 4 weeks after discontinuation. Treatments were a) vehicle, b) CS, c) calorie-restriction to match CS body weight loss (weight matched, WM), and d) calorie-restriction to match CS food intake (pair-feeding, PF). RESULTS: CS effects occurred in four phases. During days 1-10 (Phase I), CS induced rapid weight loss mainly through reduced energy intake (EI), while energy expenditure (EE) was relatively preserved. EE was significantly lower in WM rats, consistent with metabolic adaptation. During days 11-42 (Phase II), reduced body weight was maintained in the CS, WM, and PF groups, and respiratory exchange ratio converged across groups, indicating metabolic steady state had been reached. Reduced EI and preserved total EE respectively explained 86% and 14% of CS weight loss efficacy. Maintained resting/sleeping EE contributed to the total EE preservation. Treatment discontinuation (days 43-52, Phase III) caused hyperphagia and rapid weight regain. During days 53-68 (Phase IV), all groups reached metabolic steady state and weight gain returned to pretreatment rates. Body weight plateaued in approximately half the time needed to reach metabolic steady state, and metabolic adaptation reversed within ∼7 days after discontinuation. CONCLUSIONS: By persistently lowering EI and attenuating metabolic adaptation, CS enables sustained weight loss in rats; however, the reversal after treatment cessation suggests that chronic pharmacological therapy may be required to maintain weight loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research and Development, Novo Nordisk A/S, Måløv and Søborg, Denmark.
- Diabetes Complications Research Centre, University College Dublin, Ireland; Diabetes Research Centre, Ulster University, UK.
- Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIH, Bethesda, MD, USA. Electronic address: marc.reitman@nih.gov.
- Research and Development, Novo Nordisk A/S, Måløv and Søborg, Denmark. Electronic address: ruku@novonordisk.com.
Förderung
- Novo Nordisk A/S
Zitieren
APA
Petersen, L. M., Knop, F. K., le Roux, C. W., Raun, K., Reitman, M. L., & Kuhre, R. E. (2027). Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats. Molecular Metabolism, 115, 102464. https://doi.org/10.1016/j.molmet.2026.102464
Vancouver
Petersen LM, Knop FK, le Roux CW, Raun K, Reitman ML, Kuhre RE. Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats. Molecular Metabolism. 2027;115:102464. doi:10.1016/j.molmet.2026.102464
BibTeX
@article{Petersen2027,
author = {Petersen, Lisbeth M and Knop, Filip K and le Roux, Carel W and Raun, Kirsten and Reitman, Marc L and Kuhre, Rune E},
title = {Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats},
journal = {Molecular Metabolism},
year = {2027},
volume = {115},
pages = {102464},
doi = {10.1016/j.molmet.2026.102464}
}
EUVIMED